


Thalidomide-O-PEG2-propargyl

Cat. No.:	HY-126458		
CAS No.:	2098487-52-4		
Molecular Formula:	C ₂₀ H ₂₀ N ₂ O ₇		
Molecular Weight:	400.38		
Target:	E3 Ligase Ligand-Linker Conjugates		
Pathway:	PROTAC		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 120 mg/mL (299.72 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	2.4976 mL	12.4881 mL	24.9763 mL
	5 mM	0.4995 mL	2.4976 mL	4.9953 mL
	10 mM	0.2498 mL	1.2488 mL	2.4976 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3 mg/mL (7.49 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 3 mg/mL (7.49 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3 mg/mL (7.49 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology ^[1] . Thalidomide-O-PEG2-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC ₅₀ & Target	Cereblon

REFERENCES

[1]. Wurz RP, et al. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA